Antileukemic effect of interferon-alpha is mediated through down-modulation of E2F activity.
Furukawa
Y
Y
Division of Hemopoiesis, Jichi Medical School, Tochigi, Japan.
Iwase
S
S
D000970:Antineoplastic Agents / Q000633:toxicity*; D001402:B-Lymphocytes; D002051:Burkitt Lymphoma; D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins / Q000096:biosynthesis; D050684:E2F Transcription Factors; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016898:Interferon-alpha / Q000633:toxicity*; D007700:Kinetics; D007938:Leukemia; D012333:RNA, Messenger / Q000096:biosynthesis; D056465:Retinoblastoma-Binding Protein 1; D050680:Transcription Factor DP1; D014157:Transcription Factors / Q000096:biosynthesis*; D014158:Transcription, Genetic / Q000187:drug effects*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D050684:E2F Transcription Factors; D016898:Interferon-alpha; D012333:RNA, Messenger; D056465:Retinoblastoma-Binding Protein 1; D050680:Transcription Factor DP1; D014157:Transcription Factors